debrisoquin has been researched along with Alcohol Drinking in 5 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
Excerpt | Relevance | Reference |
---|---|---|
"The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96." | 7.68 | Polymorphic oxidation of debrisoquine in bladder cancer. ( Benítez, J; Cobaleda, J; Fernández-Gundín, MJ; González-Rozas, F; Ladero, JM; Llerena, A; Martínez, C; Muñoz, JJ; Prados, J; Vargas, E, 1990) |
"Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 5.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
"The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96." | 3.68 | Polymorphic oxidation of debrisoquine in bladder cancer. ( Benítez, J; Cobaleda, J; Fernández-Gundín, MJ; González-Rozas, F; Ladero, JM; Llerena, A; Martínez, C; Muñoz, JJ; Prados, J; Vargas, E, 1990) |
"Patients with bladder cancer were classified on histological criteria as having aggressive (Stage III) (34%) or nonaggressive (Stages I and II) (66%) disease." | 1.27 | Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. ( Branch, RA; Jaczq, E; Kaisary, A; McAllister, CB; Ray, WA; Smith, P; Wilkinson, GR, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shah, RR | 1 |
Oates, NS | 1 |
Idle, JR | 1 |
Smith, RL | 1 |
Lockhart, JD | 1 |
Vincent-Viry, M | 1 |
Muller, J | 1 |
Fournier, B | 1 |
Galteau, MM | 1 |
Siest, G | 1 |
Benítez, J | 1 |
Ladero, JM | 1 |
Fernández-Gundín, MJ | 1 |
Llerena, A | 1 |
Cobaleda, J | 1 |
Martínez, C | 1 |
Muñoz, JJ | 1 |
Vargas, E | 1 |
Prados, J | 1 |
González-Rozas, F | 1 |
Kaisary, A | 1 |
Smith, P | 1 |
Jaczq, E | 1 |
McAllister, CB | 1 |
Wilkinson, GR | 1 |
Ray, WA | 1 |
Branch, RA | 1 |
Steiner, E | 1 |
Iselius, L | 1 |
Alván, G | 1 |
Lindsten, J | 1 |
Sjöqvist, F | 1 |
5 other studies available for debrisoquin and Alcohol Drinking
Article | Year |
---|---|
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.
Topics: Adult; Aged; Alcohol Drinking; Angina Pectoris; Debrisoquin; Female; Humans; Isoquinolines; Liver Fu | 1982 |
Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
Topics: Administration, Oral; Adult; Alcohol Drinking; Debrisoquin; Female; Humans; Hydroxylation; Male; Mid | 1991 |
Polymorphic oxidation of debrisoquine in bladder cancer.
Topics: Aged; Alcohol Drinking; Carcinoma, Transitional Cell; Debrisoquin; Female; Humans; Isoquinolines; Ma | 1990 |
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Topics: Acetylation; Aged; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytoch | 1987 |
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alcohol Drinking; Biotransformation; Chromatography, | 1985 |